Multicord Study design<sup>27</sup>

Multicenter, open-label phase 3b study

Primary endpoint:

  • Safety of two concurrent injections of Xiapex into the same hand in subjects with multiple Dupuytren’s contractures with palpable cords
  • Followed 24 to 72 hours later by a finger extension procedure 

Secondary endpoint: 

  • Evaluate the efficacy of two concurrent injections of Xiapex

Xiapex can be used to treat 2 affected joints concurrently without a greater risk of side effects than treatment of a single joint, with the exception of skin laceration.

Improvement in fixed flextion contracture regardless of extension day27


Similar safety profile as with treatment of one cord1,27*

Are you a healthcare professional?

Dupuytren’s disease

Peyronie’s disease